Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Lineage Cell Therapeutics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 104
- −3 vs. Q2 2023
- Shares held
- 75.5M
- −133.4K (−0.2%) vs. Q2 2023
- Total value
- $89.1M
- −$17.5M (−16.4%) vs. Q2 2023
- New holders
- 6
- 26 more added
- Sold out
- 9
- 24 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LCTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 131 | $152.7M |
| Q1 2026 | 130 | $176.5M |
| Q4 2025 | 123 | $169.8M |
| Q3 2025 | 112 | $148.6M |
| Q2 2025 | 129 | $88.4M |
| Q1 2025 | 127 | $49.7M |
| Q4 2024 | 126 | $53.8M |
| Q3 2024 | 114 | $85.6M |
| Q2 2024 | 113 | $94.2M |
| Q1 2024 | 116 | $138.3M |
| Q4 2023 | 115 | $82.5M |
| Q3 2023 | 104 | $89.1M |
| Q2 2023 | 107 | $106.6M |
| Q1 2023 | 116 | $104.7M |
| Q4 2022 | 106 | $76.2M |
| Q3 2022 | 104 | $73.1M |
| Q2 2022 | 100 | $102.7M |
| Q1 2022 | 109 | $112.3M |
| Q4 2021 | 124 | $182.0M |
| Q3 2021 | 115 | $191.7M |
| Q2 2021 | 115 | $208.5M |
| Q1 2021 | 102 | $141.8M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Lineage Cell Therapeutics, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Defender Capital, LLC. | 5,184,510 | $6.12M | 2.21% | +74,800+1.5% | Added |
| Vanguard Group Inc | 8,312,332 | $9.81M | 0.00% | +1,150,633+16.1% | Added |
| BlackRock Inc. | 9,288,034 | $11.0M | 0.00% | +275,970+3.1% | Added |
| Broadwood Capital Inc | 34,935,485 | $41.2M | 3.67% | 00.0% | Unchanged |
| HRT Financial LP | 0 | $0 | 0.00% | −744,628−100.0% | Sold out |
| DAFNA Capital Management LLC | 0 | $0 | 0.00% | −140,000−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −81,816−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −42,304−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −41,181−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −13,196−100.0% | Sold out |
| Archer Investment Corp | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −972−100.0% | Sold out |
| Stonebridge Capital Advisors LLC | 0 | $0 | 0.00% | −29−100.0% | Sold out |